8-K Announcements
6Material company update
Jan 13, 2026·SEC
Material company update
Jan 6, 2026·SEC
Material company update
Dec 4, 2025·SEC
Estrella Immunopharma, Inc.(ESLA)Earnings, Financials & Key Ratios
ESLA•NASDAQ
$0.95
Price updated Jun 25, 2026
AboutEstrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Show more
- Revenue$0
- EBITDA-$13M-47.0%
- Net Income-$13M-47.6%
- EPS (Diluted)-0.35-40.0%
ESLA Price & Volume
Estrella Immunopharma, Inc. (ESLA) stock price & volume — 10-year historical chart
Loading chart...
Preclinical Capital Depletion Threatens Operational Continuity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Estrella Immunopharma remains a high-risk, pre-revenue biotechnology entity currently struggling with a severe liquidity crisis and a negative equity position of $5.3 million as of 2026Q1. The company's reliance on non-linear R&D spending, which peaked at $4.7 million in 2025Q2, necessitates immediate external capital to avoid potential insolvency. Investors should monitor the firm's ability to secure non-dilutive funding or strategic partnerships, as the current cash balance of $1.9 million is insufficient to sustain long-term clinical development."
Verdict Logic
the company faces an existential liquidity risk with only $1.9 million in cash against $8.9 million in total liabilities, suggesting imminent dilution or potential going concern issues.
ESLA Growth Metrics
Estrella Immunopharma, Inc. (ESLA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-19.34%
Return on Capital
10 Years-144.54%
5 Years-144.54%
3 Years-255.69%
Last Year-
Peers Comparison
Key metrics vs top competitors for Estrella Immunopharma, Inc. (ESLA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.95 | $40.88M | -2.71 | — | — | — | — | |
| $1.87 | $217.97M | -1.63 | -51.24% | -2056.79% | -58.89% | — | |
| $0.20 | $38.75M | -0.35 | -13.43% | -299.66% | — | — | |
| $38.24 | $7.85B | -13.81 | — | — | -68.16% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $53.63 | $8.21B | 19.36 | 87.32% | 65.95% | 87.36% | — |
Compare ESLA vs Peers
Estrella Immunopharma, Inc. (ESLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ESLA SEC Filings & Documents
Estrella Immunopharma, Inc. (ESLA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ESLA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ESLA Frequently Asked Questions
Estrella Immunopharma, Inc. (ESLA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ESLA profitable?
Estrella Immunopharma, Inc. (ESLA) reported a net loss of $13.3M for fiscal year 2025.
Dividend & Returns
What is Estrella Immunopharma, Inc.'s free cash flow?
Estrella Immunopharma, Inc. (ESLA) had negative free cash flow of $8.0M in fiscal year 2025, likely due to heavy capital investments.